Detalhe da pesquisa
1.
Extended characterization of anti-CD19 CAR T cell products manufactured at the point of care using the CliniMACS Prodigy system: comparison of donor sources and process duration.
Cytotherapy
; 2024 Mar 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38493403
2.
Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
Br J Haematol
; 193(3): 602-612, 2021 05.
Artigo
Inglês
| MEDLINE | ID: mdl-33715150
3.
Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells.
Haematologica
; 107(4): 970-974, 2022 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34911282
4.
CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study.
Leukemia
; 36(6): 1525-1532, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35468946
5.
Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients.
Nat Commun
; 12(1): 7200, 2021 12 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34893603
6.
Haploidentical donor-derived memory CAR T cells: first in human experience and in vitro correlative study.
Blood Adv
; 6(19): 5582-5588, 2022 10 11.
Artigo
Inglês
| MEDLINE | ID: mdl-35446932